CELYAD SA/ADR (CYAD) Receives Average Rating of “Buy” from Analysts
CELYAD SA/ADR (NASDAQ:CYAD) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $46.50.
A number of research firms have recently issued reports on CYAD. William Blair reissued a “buy” rating on shares of CELYAD SA/ADR in a research note on Monday, March 18th. HC Wainwright boosted their price target on shares of CELYAD SA/ADR from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, March 19th. Zacks Investment Research downgraded shares of CELYAD SA/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Finally, Piper Jaffray Companies reduced their price target on shares of CELYAD SA/ADR from $51.00 to $41.00 and set an “overweight” rating on the stock in a research note on Monday, April 1st.
A number of institutional investors and hedge funds have recently made changes to their positions in CYAD. Millennium Management LLC increased its stake in CELYAD SA/ADR by 69.6% during the 4th quarter. Millennium Management LLC now owns 90,597 shares of the company’s stock worth $1,645,000 after buying an additional 37,171 shares during the period. Victory Capital Management Inc. increased its stake in CELYAD SA/ADR by 4.1% during the 4th quarter. Victory Capital Management Inc. now owns 646,351 shares of the company’s stock worth $11,738,000 after buying an additional 25,189 shares during the period. Finally, Wells Fargo & Company MN increased its stake in CELYAD SA/ADR by 1,109.0% during the 3rd quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after buying an additional 5,545 shares during the period. 7.62% of the stock is currently owned by hedge funds and other institutional investors.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Recommended Story: What is Depreciation?
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.